Here are my thoughts. I disagree that this was the same presentation as before. I'm very excited.
1. Made the point that the low Til environment is even higher in non-melanoma cancers. If ONCS is right that it can turn non-responders into responders than there is an even HIGHER market opportunity for non-melanoma cancers than even melanoma. Melanoma is only 5% of the cancer market. Imagine the consequences. WOW!!!
2. Like my first point, he specifically stated that they are really excited about releasing pre-clinical human data on new indications. He specifically stated "human biopsy's". Further, he indicated that there will be indications "beyond IL-12." These are yet more catalysts out there. It sounded like this data would be released relatively soon.
3. He also emphasized the applicability of Immunopulse beyond cancer. He kept repeating over and over again that Immunopulse has a "Very Broad Application." I think we are going to see some pre-clinical results from the Seattle lab in the near future. Can't wait.
4. He made a statement that they are going to show through data release soon the ability of Immunopulse to stimulate mylodry(sp?)'s conversion to APC's. Please someone comment on this. It sounds cool but I don't understand it.
5. He emphasized that ONCS' safety profile is unprecedented. If you combine that with the fact that they have the highest systemic response rates that is quite a combo. I loved his line: "We are in a cool, sweet spot between safety and efficacy." Yup.
6. Said the words "Billion" and "Billions" many times. I love those words.
7.Emphasized "commercial development." Conservatively 3 years but he made it very clear that with a partner it could be a lot shorter. He used the words "significantly shorter." I think there was a lot said by Punit here. He said that the reason it would be much shorter is if it is a registration trial with the FDA on board. Well, they are meeting with the FDA in the next few weeks. Also, he made it very clear that they ARE doing this combo trial with a partner. He mentioned three names that have viable PD-1 options, Roche, BMS, and Merck. I believe there is going to be a bidding war on this after Dr. Daud is able to present at ASCO. Very exciting.
8. He commented on the S-3. He emphasized that this was for negotiations with PARTNERS!!! He hinted that they might be opportunistic for a dilution but that statement was an afterthought. He then said that some of the shelf could be used for other licensing. I took his comments to mean that part of it will be used for an imminent partnership and the rest will either be for another partnership later or licensing, purchase of assets, etc.
Those are my thoughts. Very exciting times. I'm really glad I own a lot of this stock. Today's presentation confirms even more of my belief. Good Luck to All.
AI
